Recently, Yichang Renfo Pharmaceuticals has obtained the marketing approval of remifentanil hydrochloride for injection (1mg, 2mg) from India's Central Drugs Standard Control Council (CDSCO), which is the company's first anesthetic injectable preparation that has completed clinical trials in India and has been approved according to the new drug standard.
　　India has a well-developed generic drug R&D and manufacturing industry, but the control of opioid narcotic analgesic drugs is particularly stringent, and there is no remifentanil on the market in the country yet. As a key species in the field of anesthesia and analgesia, the company's remifentanil is also highly concerned about and expected by Indian anesthesiologists. 2017, Yichang Renfu remifentanil registration application information submitted to the Indian CDSCO, which took 6 years to be finally approved, marking the Indian officials fully recognized the company's quality standards for narcotic drugs and regulated management system for controlled drugs.
　　Refentanil is used for sedation and analgesia during induction and maintenance of general anesthesia, and was firstly marketed in China by Yichang Renfu in 2003. Yichang Renfu Pharmaceuticals has been deeply engaged in the field of anesthesia and analgesia for more than 20 years, and has become a leading enterprise in the domestic segment. The company adheres to the internationalization road, and continues to expand the international market by virtue of the advantage of the integrated supply of raw materials and preparations of remifentanil, and the approval will once again enhance the competitiveness of the company's core products in the market of South Asia. The company will take this opportunity to accelerate the internationalization process, so that China-made high-quality anesthesia drugs can better benefit the people of the world.